NEW YORK, NY – Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson’s granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow or stop the progression of Parkinson’s disease. Parkinson’s is a...
research News
MIAMI, FLORIDA – Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival. AML is an aggressive and often deadly form of blood...
The combination of cancer therapy lenalidomide plus the steroid dexamethasone (together called Rd) is considered standard treatment for elderly patients with multiple myeloma. However, prolonged steroid use can be harmful for some older adults. A new study published in Blood found that switching select older patients to a lower dose...
BOONE, N.C. – A biological anthropologist from Appalachian State University working with an undergraduate student from Appalachian, an evolutionary biologist from UNC Greensboro, and a team of archaeologists from Deccan College (Pune, India) recently reported analysis of a 4000-year-old skeleton from India bearing evidence of leprosy. This skeleton represents both...
SUZHOU, China, and ROCKVILLE, Md. — Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that olverembatinib (R&D Code: HQP1351) has been included in the latest guidelines from the National Comprehensive Cancer Network (NCCN) for the management...
Four decades after a rare neurological disorder first surfaced, an Oklahoma Medical Research Foundation scientist has determined its cause – thanks to tiny flies. Scientist Wan Hee Yoon used Drosophila, the common fruit fly, to pinpoint a genetic mutation that more recently caused severe developmental and metabolic issues in four...
PHOENIX – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, has extended its intellectual property (IP) portfolio to include an exclusive option to license IP rights for the use and delivery of myxoma virus to treat certain cancers from the University of Florida Research Foundation (UFRF). This IP was developed by...
SAN DIEGO, CA — Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or...
PARIS — One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I. to identify a new generation of precision medicine targets and treatments, announced today a partnership with Assistance Publique – Hôpitaux de Paris (AP-HP), a consortium of nearly all hospitals in the greater Paris region, to...
BUFFALO, NY – A new editorial paper was published in Oncotarget’s Volume 14, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.” Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted therapies like poly (ADPribose) polymerase inhibitors...